Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Merit Medical (MMSI) or Straumann Holding AG (SAUHY) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank puts an emphasis on e ...

Key Takeaways MMSI's $22M C2 CryoBalloon deal broadens GI portfolio, targeting Barrett's esophagus treatment growth.MMSI expects $6-$8M in 2026 revenues from C2 CryoBalloon, despite near-term EPS dilution through 2025-26.MMSI strengthens GI market presence with innovative ablation tech, enhancing long-term growth outlook.Merit Medical Systems (MMSI) announced that it has signed a definitive agreement to acquire the C2 CryoBalloon technology from Pentax of America, a subsidiary of PENTAX Medical, Inc. The in ...

Asset acquisition would expand Merit’s Endoscopy portfolio with an innovative device to treat patients suffering from Barretts esophagus and other gastrointestinal disorders. Asset acquisition is projected to add approximately $6 million to $8 million of revenue in 2026 in a key gastroenterology market that leverages Merit’s existing commercial footprint. SOUTH JORDAN, Utah, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announ ...

Core Insights - PENTAX Medical has entered into an asset purchase agreement with Merit Medical Systems for the acquisition of the C2 CryoBalloon technology, which aligns with its strategic focus on core flexible reusable endoscopy solutions [1][2][4] - The C2 CryoBalloon technology, which has been part of PENTAX Medical's portfolio since 2017, provides a minimally invasive treatment option for patients with Barrett's Esophagus and other gastrointestinal disorders [2][3] - The transition allows PENTAX Medical to concentrate on its core strengths while Merit Medical is expected to enhance the adoption and impact of the C2 technology [3][4] Company Overview - PENTAX Medical is a division of HOYA Group, specializing in flexible, reusable endoscopy solutions, and is committed to delivering high-quality imaging and intuitive solutions for healthcare professionals [5] - Merit Medical, founded in 1987, develops and distributes proprietary medical devices across various medical fields, including endoscopy, and employs approximately 7,300 individuals globally [6] - HOYA Corporation, established in 1941, is a leader in healthcare and technology innovation, providing advanced products for life care and supporting various industries with high-precision components [7]

Core Viewpoint - Merit Medical Systems, Inc. is set to release its financial results for Q3 2025 on October 30, 2025, and will hold an investor conference call on the same day [1]. Company Overview - Merit Medical Systems, Inc. was founded in 1987 and specializes in the development, manufacture, and distribution of proprietary medical devices for interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy [3]. - The company serves a global customer base with a sales force and clinical support team of over 800 individuals and employs approximately 7,400 people worldwide [3]. Investor Communication - Investors can pre-register for the conference call through a provided link, and a live webcast along with a slide deck will be accessible [2]. - The conference call is scheduled for October 30, 2025, at 5:00 p.m. Eastern Time [1].

Core Viewpoint - The comparison between Merit Medical (MMSI) and Straumann Holding AG (SAUHY) indicates that MMSI is currently more attractive to value investors due to its stronger earnings outlook and better valuation metrics [1][3][7]. Valuation Metrics - MMSI has a forward P/E ratio of 22.61, while SAUHY has a higher forward P/E of 28.18 [5]. - The PEG ratio for MMSI is 2.32, compared to SAUHY's PEG ratio of 2.61, suggesting that MMSI may offer better value relative to its expected earnings growth [5]. - MMSI's P/B ratio stands at 3.27, significantly lower than SAUHY's P/B ratio of 6.92, indicating that MMSI is more undervalued based on its book value [6]. Earnings Outlook - MMSI has experienced stronger estimate revision activity, which is a positive indicator for its future earnings potential [7]. - The Zacks Rank for MMSI is 2 (Buy), while SAUHY has a Zacks Rank of 4 (Sell), further supporting the conclusion that MMSI is the superior option for value investors [3][7]. Value Grades - Based on various valuation metrics, MMSI holds a Value grade of B, whereas SAUHY has a Value grade of D, reinforcing the notion that MMSI is a more attractive investment [6].

Core Insights - Merit Medical Systems, Inc. has achieved a significant milestone with SCOUT® Radar Localization being used in 750,000 patients globally, enhancing breast cancer treatment outcomes [1][3][6] Company Overview - Merit Medical, founded in 1987, specializes in the development, manufacture, and distribution of proprietary medical devices for interventional, diagnostic, and therapeutic procedures across various medical fields including cardiology, radiology, oncology, critical care, and endoscopy [8] Product Details - SCOUT® Radar Localization is a wire-free, non-radioactive localization technology that allows for precise surgical removal of abnormal breast tissue, minimizing trauma to surrounding healthy tissue [3][4] - The system utilizes a tiny reflector, about the size of a grain of rice, enabling targeting accuracy within +/- 1 mm, which contributes to more successful surgeries and improved patient care [3] - SCOUT supports various treatment needs, including placement in breast tissue and lymph nodes, and can be utilized pre- or post-neoadjuvant chemotherapy, at the time of biopsy, and for bracketing techniques [4] - The introduction of SCOUT MD™ enhances the localization system with four reflector shapes and distinct radar signals for improved tumor margin mapping and localization of multiple lesions or nodes [5] Market Impact - SCOUT has been referenced in over 100 clinical publications, with nearly 8,500 patients noted, and is utilized in 50 countries, performing more than 500 cases daily, totaling 10,000 cases monthly [6] - Over 1,100 facilities worldwide prefer SCOUT for wire-free localization, indicating strong market adoption and trust in the technology [6] Leadership Perspective - The CEO of Merit Medical expressed pride in the positive impact of SCOUT on patients' lives, emphasizing the company's commitment to supporting individuals with breast cancer beyond just Breast Cancer Awareness Month [7]

Core Insights - Loomis Sayles Small Cap Growth Fund reported a return of 9.37% for Q2 2025, underperforming the Russell 2000 Growth Index which returned 11.97% due to security selection issues in the information technology and financial sectors [1] Company Overview - Merit Medical Systems, Inc. (NASDAQ:MMSI) is a manufacturer of single-use medical products, focusing on interventional cardiology and radiology [2][3] - As of September 29, 2025, Merit Medical's stock closed at $80.86 per share, with a market capitalization of $4.788 billion [2] Financial Performance - In Q2 2025, Merit Medical reported revenues of $382.5 million, reflecting a 13% year-over-year increase on a GAAP basis and a 12.5% increase on a constant currency basis [4] Market Position - Merit Medical is not among the 30 most popular stocks among hedge funds, with 26 hedge fund portfolios holding the stock at the end of Q2 2025, an increase from 24 in the previous quarter [4] - The company faces challenges due to tariff and trade policy concerns, as approximately 40% of its revenues are generated outside the US [3]

Core Insights - Merit Medical Systems (MMSI) has received CE Mark approval for its Embosphere Microspheres, allowing for genicular artery embolisation (GAE) to treat knee osteoarthritis (OA), providing a minimally invasive treatment option for a common and debilitating condition [1][4][10] Company Summary - The CE Mark approval validates Merit Medical's Embosphere technology, which has shown consistent clinical outcomes across various therapeutic areas, reinforcing the company's leadership in minimally invasive therapies [2][4] - Following the announcement, MMSI's stock experienced a decline of 5.2% at market close, with a year-to-date loss of 11.6%, contrasting with the industry's 1.8% decline and the S&P 500's gain of 12.8% [3] - The approval expands the addressable market for MMSI, tapping into a large and underserved patient population, which is expected to create durable revenue opportunities and enhance the company's competitive edge in pain management [4][9] Product Insights - The Embosphere Microspheres have been clinically proven to provide over 75% of patients with meaningful pain reduction and improved function for up to 24 months, outperforming corticosteroid injections in terms of consistency and duration of benefits [10][11] - The technology has over 25 years of clinical use and is supported by more than 130 pivotal studies, establishing its reliability in procedures involving small arteries [11] Industry Outlook - The global osteoarthritis therapeutics market is projected to grow from an estimated $9.13 billion in 2024 to $13.57 billion by 2030, with a compound annual growth rate (CAGR) of 6.89% from 2025 to 2030, driven by the increasing prevalence of OA and significant R&D investments [12]

Core Insights - Merit Medical Systems, Inc. announced that Embosphere Microspheres are now indicated in the EU for genicular artery embolisation (GAE) to treat knee osteoarthritis (OA) [1][4] Group 1: Company Overview - Merit Medical is a global leader in healthcare technology, founded in 1987, focusing on the development, manufacture, and distribution of proprietary disposable medical devices [8] - The company employs approximately 7,300 people worldwide and serves client hospitals with a sales force and clinical support team of over 800 individuals [8] Group 2: Product and Treatment Insights - Embosphere Microspheres have been proven effective in treating knee OA, with over 75% of patients achieving clinical success and significant pain reduction sustained through 24 months [4][6] - GAE selectively reduces blood flow to the inflamed synovium, leading to meaningful reductions in knee pain and improved joint function, representing a growing trend in minimally invasive pain management therapies [3][4] Group 3: Market Context - Osteoarthritis is the most common type of arthritis, affecting approximately 595 million people globally, with knee OA being the most frequently affected joint [2] - The prevalence of OA is expected to increase due to aging populations, rising injury rates, and obesity [2] Group 4: Competitive Advantage - Embosphere's proprietary formulation and spherical shape provide complete and durable occlusion of targeted blood vessels, offering consistent and reliable performance, especially in treating small genicular arteries [5][6] - Compared to corticosteroid injections, GAE with Embosphere has shown consistently higher clinical success rates and greater improvements in pain and quality of life at three months [4]